Clinical Trial Detail

NCT ID NCT01774344
Title Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma (RESORCE)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements no
Sponsors Bayer
Indications

hepatocellular carcinoma

Therapies

Regorafenib

Age Groups: adult

No variant requirements are available.